Nitriles

Eisai's Anti-Epileptic Drug Fycompa Approved In China As Monotherapy For Partial-Onset Seizures And Pediatric Indication For Partial-Onset Seizures

Retrieved on: 
Monday, August 2, 2021
Anticonvulsants, Clinical medicine, Nitriles, Perampanel, Pyridines, Eisai, Medicine, Health, Epilepsy, Seizure, Generalized epilepsy, Syndromes

Fycompa has already been approved in China as an adjunctive treatment for partial-onset seizures with or without secondarily generalized seizures in patients with epilepsy 12 years of age and older.

Key Points: 
  • Fycompa has already been approved in China as an adjunctive treatment for partial-onset seizures with or without secondarily generalized seizures in patients with epilepsy 12 years of age and older.
  • Through this approval, Fycompa is now available in China as a monotherapy and an adjunctive treatment for partial-onset seizures (with or without secondarily generalized seizures) in patients with epilepsy 4 years of age and older.
  • Fycompa is a first-in-class AED and a once-daily tablet discovered at Eisai's Tsukuba Research Laboratories.
  • Eisai seeks to address the diverse needs of, as well as increase the benefits provided to, patients with epilepsy and their families.

Laekna Therapeutics will present two clinical study results in ESMO 2021

Retrieved on: 
Monday, July 26, 2021
Chemical compounds, Drugs, Cancer, Nonsteroidal antiandrogens, Prostate cancer, Nitriles, MCRPC, Prostvac, James L. Gulley

This ClinicalTrials NCT03843918 is a phase I monotherapy dose-escalation study of LAE001, in patients with metastatic castration-resistant prostate cancer (mCRPC).

Key Points: 
  • This ClinicalTrials NCT03843918 is a phase I monotherapy dose-escalation study of LAE001, in patients with metastatic castration-resistant prostate cancer (mCRPC).
  • Laekna plan to further develop LAE001 to treat patients with mCSPC, who usually have a much longer treatment duration, and would benefit more from using LAE001.
  • The global randomized, open-label, multi-center Phase 2 PROFECTA-II clinical trial of afuresertib is the world's first registration-directed clinical study of a pan-AKT kinase inhibitor to treat platinum-resistant ovarian cancer.
  • Laekna is committed to a science-based, innovation-driven approach to create an international leading clinical research and development platform for the development of first-in-class and best-in-class innovative drugs.

Xenikos Announces T-Guard® Phase 3 Clinical Update and Outlines 2021-2022 Corporate Objectives

Retrieved on: 
Monday, July 19, 2021
Chemical compounds, Medical specialties, Clinical medicine, Cyclopentanes, Nitriles, Pyrazoles, Ruxolitinib, Hematopoietic stem cell transplantation

Xenikos expects to commence this Phase 3 study in the second half of 2021.

Key Points: 
  • Xenikos expects to commence this Phase 3 study in the second half of 2021.
  • Initiate new Phase 3 study evaluating T-Guard versus ruxolitinib in patients with SR-aGVHD following allo-HSCT in the second half of 2021.
  • Complete safety run-in phase of Phase 3 study mid 2022.
  • Mehdi Hamadani, Protocol Officer, Scientific Director of CIBMTR, Medical College of Wisconsin; John Levine, Protocol Co-chair, Director of BMT Clinical Research, Mt.

ViiV Healthcare study shows new long-acting HIV regimen Cabenuva (cabotegravir/rilpivirine) can be successfully implemented in broad range of US healthcare practices, even during COVID-19

Retrieved on: 
Saturday, July 17, 2021
AIDS, Health, Infectious diseases, Clinical trials, Pharmaceutical, Biotechnology, Chemical compounds, Integrase inhibitors, Non-nucleoside reverse transcriptase inhibitors, Organic compounds, Nitriles, Pyrimidines, Rilpivirine, Cabotegravir, Prevention of HIV/AIDS, HIV Prevention Trials Network, Cabenuva (cabotegravir and rilpivirine)8, ViiV Healthcare, GSK, CABENUVA (CABOTEGRAVIR AND RILPIVIRINE)8, VIIV HEALTHCARE, GSK

Additionally, this regimen remained highly acceptable both to healthcare providers and people living with HIV and was strongly preferred by study participants to daily oral therapy.

Key Points: 
  • Additionally, this regimen remained highly acceptable both to healthcare providers and people living with HIV and was strongly preferred by study participants to daily oral therapy.
  • A corresponding trial in Europe, CARISEL, is examining the implementation of long-acting cabotegravir and rilpivirine, dosed every 2-months in certain European healthcare settings.
  • Marketing Authorisations for the long-acting regimen of cabotegravir and rilpivirine were granted by the European Medicines Agency in December 2020.
  • Sustainment of implementation strategies was assessed via surveys and semi-structured interviews of staff study participants as well as patient study participants.

Incyte Announces Positive Phase 3 REACH3 Study Data Published in NEJM for Ruxolitinib (Jakafi®) in Chronic Graft-Versus-Host Disease

Retrieved on: 
Wednesday, July 14, 2021
Biotechnology, Pharmaceutical, Health, Medical specialties, Clinical medicine, Chemical compounds, Blood disorders, Transplantation medicine, Nitriles, Pyrazoles, Ruxolitinib, Graft-versus-host disease, Neutropenia, Cytopenia, REACH3, REACH, Jakafi® (ruxolitinib), Incyte, REACH3, REACH, JAKAFI® (RUXOLITINIB), INCYTE

Results from the REACH3 study published in NEJM are extremely compelling and underscore the potential benefits ruxolitinib can offer appropriate patients facing the serious complications associated with chronic GVHD, said Peter Langmuir, M.D., Group Vice President, Oncology Targeted Therapies, Incyte.

Key Points: 
  • Results from the REACH3 study published in NEJM are extremely compelling and underscore the potential benefits ruxolitinib can offer appropriate patients facing the serious complications associated with chronic GVHD, said Peter Langmuir, M.D., Group Vice President, Oncology Targeted Therapies, Incyte.
  • BAT arms were thrombocytopenia (15.2% vs. 10.1%), anemia (12.7% vs. 7.6%), neutropenia (8.5% vs. 3.8%) and pneumonia (8.5% vs. 9.5%).
  • Mortality rates were similar across treatment arms (18.8% in the ruxolitinib arm vs. 16.5% in the BAT arm)1.
  • Deaths reported as primarily due to chronic GVHD complications and/or its treatment were higher in the ruxolitinib vs.

Dipeptidyl Peptidase 4 Inhibitors Pipeline Research Report 2021 - ResearchAndMarkets.com

Retrieved on: 
Wednesday, July 7, 2021
Health, Diabetes, Proteases, Dipeptidyl peptidase-4 inhibitors, Dipeptidyl peptidase, Nitriles, Chemistry, Organic compounds, Chemical compounds, Tertiary alcohols, Piperidines, Dipeptidyl-peptidase IV family, Vildagliptin

The "Dipeptidyl Peptidase 4 Inhibitors - Pipeline Insight, 2021" drug pipelines has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Dipeptidyl Peptidase 4 Inhibitors - Pipeline Insight, 2021" drug pipelines has been added to ResearchAndMarkets.com's offering.
  • This "Dipeptidyl peptidase 4 inhibitors - Pipeline Insight, 2021" report provides comprehensive insights about 8+ companies and 8+ pipeline drugs in Dipeptidyl peptidase 4 inhibitors pipeline landscape.
  • The companies and academics are working to assess challenges and seek opportunities that could influence Dipeptidyl peptidase 4 inhibitors R&D.
  • Dipeptidyl peptidase 4 inhibitors pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration.

Worldwide Acetonitrile Industry to 2025 - Key Drivers, Challenges and Trends - ResearchAndMarkets.com

Retrieved on: 
Monday, July 5, 2021
Other Manufacturing, Manufacturing, Chemistry, Physical sciences, Natural sciences, Acetonitrile, Ligands, Nitriles, Solvents, Chromatography, High-performance liquid chromatography, Marketplace

The publisher has been monitoring the acetonitrile market and it is poised to grow by 36.07 thousand tons during 2021-2025, progressing at a CAGR of almost 6% during the forecast period.

Key Points: 
  • The publisher has been monitoring the acetonitrile market and it is poised to grow by 36.07 thousand tons during 2021-2025, progressing at a CAGR of almost 6% during the forecast period.
  • The report on the acetonitrile market provides a holistic analysis, market size and forecast, trends, growth drivers, and challenges, as well as vendor analysis covering around 25 vendors.
  • In addition, the high consumption of acetonitrile in the pharmaceutical industry is anticipated to boost the growth of the market as well.
  • This study identifies the high volume consumption of acetonitrile in HPLC as one of the prime reasons driving the acetonitrile market growth during the next few years.

TG Therapeutics Announces Presentation of Data from the ULTIMATE I & II Phase 3 Trials of Ublituximab in Multiple Sclerosis at 7th Congress of the European Academy of Neurology

Retrieved on: 
Friday, June 18, 2021
Chemistry, Physical sciences, Materials, Anilides, Immunosuppressants, Sanofi, Enols, Nitriles, Teriflunomide, Gadolinium

In ULTIMATE II, treatment with ublituximab resulted in an ARR of 0.091 compared to 0.178 for teriflunomide, representing a relative reduction of approximately 50% (p=0.0022).

Key Points: 
  • In ULTIMATE II, treatment with ublituximab resulted in an ARR of 0.091 compared to 0.178 for teriflunomide, representing a relative reduction of approximately 50% (p=0.0022).
  • Total number ofT1 Gadolinium (Gd)enhancing lesionswere reduced as a result of ublituximab treatment by 97% and 96% relative to treatment with teriflunomide in ULTIMATE I & II, respectively(p
  • New or enlargingT2 lesionswere reduced as a result of ublituximab treatment by 92% and 90% relative to treatment with teriflunomide in ULTIMATE I & II, respectively(p
  • The ULTIMATE I & II trials enrolled a total of 1,094 patients with RMS across 10 countries.

European Commission approves Aubagio® (teriflunomide) as the first oral MS therapy for first-line treatment of children and adolescents living with relapsing-remitting multiple sclerosis

Retrieved on: 
Friday, June 18, 2021
Multiple sclerosis, Medicine, Medical specialties, Clinical medicine, Nitriles, Immunosuppressants, Autoimmune diseases, Teriflunomide, Multiple sclerosis drug pipeline, Multiple sclerosis research

PARIS June 18, 2021 - The European Commission (EC) has approved Aubagio (teriflunomide) for the treatment of pediatric patients 10 to 17 years of age with relapsing-remitting multiple sclerosis (RRMS).

Key Points: 
  • PARIS June 18, 2021 - The European Commission (EC) has approved Aubagio (teriflunomide) for the treatment of pediatric patients 10 to 17 years of age with relapsing-remitting multiple sclerosis (RRMS).
  • The approval confirms Aubagio as the first oral multiple sclerosis (MS) therapy for first-line treatment of children and adolescents with MS in the European Union.
  • The European approval of Aubagio in pediatrics means young people with MS have a new treatment option, and importantly - one that can offer meaningful improvement in managing this serious disease.
  • Multiple sclerosis is a chronic neurodegenerative disease in which a person's immune system causes damage to the brain and spinal cord.

Lexaria Hits Important Anti-Viral Milestone with In Vitro Test of DehydraTECH(TM)

Retrieved on: 
Thursday, June 17, 2021
Organic compounds, Antiviral drugs, Drugs, Chemistry, Gilead Sciences, COVID-19 drug development, Nitriles, Remdesivir

"This test is conducted as a pass/fail," said Chris Bunka, CEO of Lexaria Bioscience.

Key Points: 
  • "This test is conducted as a pass/fail," said Chris Bunka, CEO of Lexaria Bioscience.
  • The first and most obvious is that DehydraTECHTM works with these important antivirals.
  • The second is that it opens the door to an antiviral market projected to be worth USD$44 billion by 2026.
  • Lexaria would like to emphasize that the use of DehydraTECHTM with Remdesivir does not create a "cure" for COVID-19.